FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma March 24, 2026
Positive End-of-Phase 2 Meeting with FDA Regarding the Design of a Ph 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma Announced March 24, 2026
NCCN Guidelines Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease March 24, 2026
Opdivo combination regimens received FDA approval for previously untreated, Stage III or IV cHL and EC approval in R/R cHL after one prior line of therapy March 24, 2026
